UNASSIGNED: This phase II study investigates the efficacy of bevacizumab (BEV), a VEGF binding monoclonal antibody, in patients with progressive Grade I (G1M), Grade II (G2M), Grade III (G3M) meningioma, and other non-parenchymal tumors including vestibular schwannoma (n = 4) and hemangiopericytoma (n = 4) with the primary endpoint of progression-free survival rate at 6-months (PFS-6). Non-meningiomas were included with the respective meningioma grade in the analysis. Secondary endpoints include median overall survival (mOS) and response rate.
UNASSIGNED: Fifty Patients (26 women; median age 54 years; range 23-81), 42 with progressive meningioma were treated: 10 G1M, 20 G2M, and 12 G3M. Prior treatments include surgical resection (41 patients), radiosurgery (24 patients), external beam radiotherapy (28 patients), and chemotherapy (14 patients). Median infusions administered were 16 (range, 2-68). Response was graded using the Macdonald\'s criteria. PFS-6, median PFS, and mOS were 87%, 22 months, 35 months for G1M; 77%, 23 months, 41 months for G2M; and 46%, 8 months, 12 months for G3M. Best radiographic responses include stable disease (G1M: 100%; G2M: 85%; G3M: 82%); partial response (G1M: 0%; G2M: 5%; G3M: 0%) and progressive disease (G1M: 0%; G2M: 10%; G3M:18%). The most common toxicities were hypertension (n = 19, 42.2%), proteinuria (n = 16, 35.6%), and fatigue (n = 14, 31.1%).
UNASSIGNED: This study showed BEV is well tolerated and appears to be a promising systemic treatment option for patients with recurrent and refractory meningiomas.
未经评估:这项II期研究调查了贝伐单抗(BEV)的疗效,VEGF结合单克隆抗体,在进行性I级(G1M)患者中,二级(G2M),III级(G3M)脑膜瘤,和其他非实质肿瘤,包括前庭神经鞘瘤(n=4)和血管外皮细胞瘤(n=4),主要终点为6个月无进展生存率(PFS-6)。非脑膜瘤包括在分析中的相应脑膜瘤等级。次要终点包括中位总生存期(mOS)和缓解率。
未经评估:50名患者(26名女性;平均年龄54岁;范围23-81),治疗42例进行性脑膜瘤:10G1M,20G2M,12G3M先前的治疗包括手术切除(41例),放射外科(24名患者),外束放疗(28例),和化疗(14例)。中位输注次数为16次(范围,2-68).使用麦克唐纳的标准对反应进行分级。PFS-6,中位数PFS,MOS为87%,22个月,G1M为35个月;77%,23个月,G2M为41个月;46%,8个月,12个月为G3M。最佳放射学应答包括疾病稳定(G1M:100%;G2M:85%;G3M:82%);部分应答(G1M:0%;G2M:5%;G3M:0%)和疾病进展(G1M:0%;G2M:10%;G3M:18%)。最常见的毒性是高血压(n=19,42.2%),蛋白尿(n=16,35.6%),和疲劳(n=14,31.1%)。
UNASSIGNED:这项研究表明,BEV具有良好的耐受性,似乎是复发性和难治性脑膜瘤患者的一种有希望的全身治疗选择。